Year All20242023202220212020201920182017201620152014 Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3 May 24, 2021 Read More Abivax suspends trading of its shares until the publication of ABX464 Phase 2b results in ulcerative colitis May 24, 2021 Read More Abivax publishes Universal Registration Document 2021 “Document d’Enregistrement Universel” April 30, 2021 Read More Abivax Hosting Key Opinion Leader Webinar on ABX464 for the Treatment of Ulcerative Colitis April 19, 2021 Read More Abivax completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis April 14, 2021 Read More Abivax reports 2020 financial results and operations update March 31, 2021 Read More Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy March 05, 2021 Read More Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal “Gastroenterology" March 03, 2021 Read More Abivax appoints Dr Sophie Biguenet as Chief Medical Officer March 01, 2021 Read More Abivax publishes review in Drug Discovery Today on mechanism of action and transformative potential of ABX464 as therapy for inflammatory diseases January 05, 2021 Read More
Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3 May 24, 2021 Read More
Abivax suspends trading of its shares until the publication of ABX464 Phase 2b results in ulcerative colitis May 24, 2021 Read More
Abivax publishes Universal Registration Document 2021 “Document d’Enregistrement Universel” April 30, 2021 Read More
Abivax Hosting Key Opinion Leader Webinar on ABX464 for the Treatment of Ulcerative Colitis April 19, 2021 Read More
Abivax completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis April 14, 2021 Read More
Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy March 05, 2021 Read More
Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal “Gastroenterology" March 03, 2021 Read More
Abivax publishes review in Drug Discovery Today on mechanism of action and transformative potential of ABX464 as therapy for inflammatory diseases January 05, 2021 Read More
